Subscribe to our Newsletters !!
How are viruses different from bacteria apex ? O
Industries and scientific fields use conductivity
Insects that are given more attention and reverenc
Alembic Pharmaceuticals Limited appoints Mr. Manis
The importance of comparing the treatment of asthm
It is important to understand that natural remedie
Dear Readers, Welcome to the latest issue of The Magazine
The World Health Organization says it has cleared the Pfizer-BioNTech coronavirus vaccine for emergency use, meaning poorer countries may soon get access to the shooter already available in Europe and North America.
Every country which has a drug regulatory agency will need to issue its own approval for any COVID-19 vaccine, but states with weak systems usually rely on WHO to vet the shots.
The international body said late Thursday that the decision to issue its first emergency use validation for a COVID-19 vaccine”opens the door for countries to expedite their own regulatory approval processes to administer and import the vaccine.”
The UN health agency said its inspection found the Pfizer-BioNTech vaccine, which has already received clearance in the United States, Britain, the European Union and a dozen other nations,”fulfilled the must-have criteria for efficacy and safety set from WHO.”
The BioNTech-Pfizer vaccine has to be kept at ultra-frozen temperatures, a big hurdle for developing countries where the essential freezers and reliable electricity supply may not be available.
“This requirement makes the vaccine harder to deploy in settings where ultra-cold chain equipment may not be available or accessible,” WHO said, adding that it was”working to support countries in assessing their delivery plans and preparing for use where possible”.
